Atypical PKC signaling in lung cancer stem cells

肺癌干细胞中的非典型 PKC 信号传导

• 批准号: 8244684
• 负责人: Alan P. Fields
• 金额: $ 8.42万
• 依托单位: MAYO CLINIC JACKSONVILLE
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-07-01 至 2012-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8244684
• 关键词: Alveolar; Aurothiomalate; Behavior; Cancer Etiology; Cancer Patient; Cell Line; Cells; Cessation of life; Chromatin; Data; Epigenetic Process; Exhibits; Genes; Genetic; Goals; Growth; Homologous Gene; Human; Human Resources; In Vitro; Lung; Lung Adenocarcinoma; Lung Neoplasms; Maintenance; Malignant Neoplasms; Malignant neoplasm of lung; Mediating; Mouse Protein; Non-Small-Cell Lung Carcinoma; Oncogenes; Oncogenic; Pathway interactions; Patients; Play; Polycomb; Process; Prognostic Marker; Property; Protein Kinase; Protein Kinase C; Role; Signal Pathway; Signal Transduction; Squamous Cell Lung Carcinoma; Stem cells; Testing; Therapeutic Agents; Transgenic Mice; Translating; Tumor-Derived; Tumorigenicity; United States; atypical protein kinase C; base; cancer initiation; cancer stem cell; cell growth; cell transformation; genetic manipulation; in vivo; in vivo Model; inhibitor/antagonist; insight; lung tumorigenesis; new therapeutic target; novel; novel therapeutics; prognostic; self-renewal; stem; stem cell niche; therapeutic target; tissue resource; tool; treatment strategy; tumor; tumor growth; tumorigenic

Project Summary The goals of this project are to elucidate protein kinase C (PKC) signaling mechanisms that contribute to lung cancer initiation and maintenance and translate these mechanistic insights into better prognostic and treatment strategies. We recently identified the atypical PKCi gene PRKCI as a human oncogene in the lung. Furthermore, we find that the mouse PKCi gene Prkci is required for the very earliest steps of lung tumorigenesis induced by oncogenic Kras in vivo. Specifically, Prkci is necessary for Kras-mediated transformation of bronchio-alveolar stem cells (BASCs), the putative cell of origin of Kras-mediated lung tumorigenesis. Genetic disruption of Prkci, or treatment with the PKC¿ inhibitor aurothiomalate (ATM), blocks Kras-mediated expansion and morphological transformation of BASC in vitro and in vivo, and lung tumor growth in vivo. Preliminary results suggest that Kras-, Prkci-mediated expansion of BASCs involves induction of the polycomb gene Bmi1. Bmi1 is an epigenetic chromatin modifier/transcriptional regulator implicated in cancer stem cell identity and self-renewal. Like Prkci, Bmi1 is necessary for Kras-mediated BASC expansion and lung tumorigenesis. Based on these preliminary data, we hypothesize that Prkci drives Kras-mediated BASC transformation and lung tumorigenesis, at least in part, through activation of the Bmi1 signaling pathway. We further hypothesize that a similar PKCi-Bmi1 signaling axis plays a critical role in the maintenance, expansion and tumorigenic potential of human lung cancer stem cells. Finally, we hypothesize that ATM will effectively inhibit the self-renewal and tumorigenic potential of human lung cancer stem cells. We will test these hypotheses through completion of two interrelated specific aims. In Aim 1 we will assess the role of the PKCi-Par6-Ect2-Rac1 signaling axis in BASC transformation and dissect the mechanism of crosstalk between PKCi and Bmi1 signaling in these cells. In Aim 2 we will determine the role of PKCi and Bmi1 signaling in the self-renewal and tumor initiating activity of lung cancer stem cells. We will develop and characterize a panel of lung cancer stem cell lines from primary lung tumors. Completion of these studies will provide important new mechanistic insight into oncogenic PKCi signaling in putative lung cancer stem cells, enhance our understanding of Kras-mediated lung tumorigenesis, and assess the efficacy of a novel therapeutic agent that targets a critical oncogenic pathway in lung cancer stem cells. These studies have important implications for PKCi as a therapeutic target and for the use of ATM as a novel therapeutic for the treatment of lung cancer.

项目摘要 本项目的目的是阐明蛋白激酶C（PKC）信号机制，有助于肺 并将这些机制见解转化为更好的预后和治疗 战略布局我们最近确定了非典型PKCi基因PRKCI作为一种人类癌基因在肺。 此外，我们发现小鼠PKCi基因Prkci是肺发育的最早阶段所必需的， 体内致癌Kras诱导的肿瘤发生。具体而言，Prkci对于Kras介导的 支气管肺泡干细胞（BASCs）的转化，Kras介导的肺的假定起源细胞 肿瘤发生Prkci的遗传破坏，或用PKC抑制剂aurothiomalate（ATM）治疗， Kras介导的BASC体内外扩增、形态转化及肺肿瘤 体内生长初步结果表明，Kras，Prkci介导的BASCs扩增涉及诱导 polycomb基因Bmi 1。Bmi 1是一种表观遗传染色质修饰因子/转录调节因子， 癌症干细胞身份和自我更新。与Prkci一样，Bmi 1是Kras介导的BASC扩增所必需的 和肺肿瘤发生。基于这些初步数据，我们假设Prkci驱动Kras介导的 BASC转化和肺肿瘤发生，至少部分通过激活Bmi 1信号传导 通路我们进一步假设，类似的PKCi-Bmi 1信号轴在细胞凋亡中起着关键作用。 人肺癌干细胞的维持、扩增和致瘤潜能。最后，我们假设 ATM将有效抑制人肺癌干细胞的自我更新和致瘤潜力。我们 将通过完成两个相互关联的具体目标来检验这些假设。在目标1中，我们将评估 BASC转化中PKCi-Par 6-Ect 2-Rac 1信号轴的相互作用，并剖析了串扰的机制 PKCi和Bmi 1信号之间的联系。在目标2中，我们将确定PKCi和Bmi 1的作用。 在肺癌干细胞的自我更新和肿瘤启动活性的信号传导。创新和 表征一组来自原发性肺肿瘤的肺癌干细胞系。完成这些研究将 为推定的肺癌干细胞中致癌PKCi信号传导提供了重要的新机制见解， 增强我们对Kras介导的肺肿瘤发生的理解，并评估一种新的 靶向肺癌干细胞中的关键致癌途径的治疗剂。这些研究 PKCi作为治疗靶点和ATM作为新的治疗药物的使用具有重要意义。 肺癌的治疗